Biotinylated Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Complex Protein (Monomer, MALS verified)

This gene encodes an antigen that is preferentially expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. The encoded protein acts as a repressor of retinoic acid receptor, and likely confers a growth advantage to cancer cells via this function. Alternative splicing results in multiple transcript variants. The PRAME (SLLQHLIGL) was shown to be recognized by HLA-A*0201 tumor-infiltrating lymphocytes from melanoma patients, and therefore it is widely been studied in TCR-T studies. The Human HLA-A*0201 PRAME (SLLQHLIGL) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and PRAME (SLLQHLIGL) peptide.

Biotinylated Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Complex Protein is produced by co-expression of HLA and B2M loaded with PRAME peptide. This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) . The protein has a calculated MW of 51.3 kDa. The protein migrates as 58-61 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

● -20°C to -70°C for 12 months in lyophilized state; ● -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Immobilized Biotinylated Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Complex Protein (Cat. No. HLE-H82E8) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.2-4 ng/mL (QC tested).